ReviewJournal of hematology & oncology2012
Molecular functions of metallothionein and its role in hematological malignancies.
Review in Journal of hematology & oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Pooled it
- Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors.Clinical pharmacokinetics · 2026Article
- Targeting Reactive Species Stress and Nutrient Sensing to Enhance NK-Cell Function: Mechanistic Strategies for Overcoming Pancreatic Cancer Progression and Resistance Through Supplement Therapy.International journal of molecular sciences · 2026Review
- Metallothionein Isoforms in Acute Myeloid Leukemia: Roles in Survival, Differentiation, and Stress Adaptation.Hematology reports · 2026Review
- Icaritin inhibits breast cancer through activating MT1X to promote ferroptosis and synergizing with NF-κB pathway suppression.Frontiers in oncology · 2026Article
- Emerging Roles of Metallothioneins in Human Pathophysiology: A Review.Health science reports · 2025Article
- Metallothionein 1X is a tumor suppressor gene and inhibits oxidative stress and metastasis in renal cell carcinoma.Discover oncology · 2025Article
- MT1H inhibits the growth of gastric cancer by regulating SLC6A19/TTC39B/ADM2 and activating p53-dependent autophagy.Scientific reports · 2025Article
- Differential Gene Regulatory Network Analysis between Azacitidine-Sensitive and -Resistant Cell Lines.International journal of molecular sciences · 2024Article
- Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets.Signal transduction and targeted therapy · 2024Review
- Article
- Development of anMolecular therapy. Methods & clinical development · 2023Article
- Metallothioneins, a Part of the Retinal Endogenous Protective System in Various Ocular Diseases.Antioxidants (Basel, Switzerland) · 2023Review
- The Difference in Zinc Concentrations Required for Induction among Metallothionein Isoforms Can Be Explained by the Different MTF1 Affinities to MREs in Its Promoter.International journal of molecular sciences · 2022Article
- Article
- Structural Characterization and In Vitro Antioxidant Activity of Metallothionein fromMolecules (Basel, Switzerland) · 2022Article
- Construction and validation of a novel prognostic model for lung squamous cell cancer based on N6-methyladenosine-related genes.World journal of surgical oncology · 2022Article
- BCRP/Drug metabolism and disposition: the biological fate of chemicals · 2021Article
- Antioxidant Defenses in the Human Eye: A Focus on Metallothioneins.Antioxidants (Basel, Switzerland) · 2021Review
- Kevetrin induces apoptosis in TP53 wild‑type and mutant acute myeloid leukemia cells.Oncology reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metallothionein (MT) was reported to be a potential negative regulator of apoptosis, and various reports have suggested that it may play roles in carcinogenesis and drug resistance, in at least a portion of cancer cells. The author summarizes the current understanding of the molecular functions of MT for tumor cell growth and drug resistance. These activities are regulated through intracellular metal ion modulation and free radical scavenging. Compared with analyses of solid tumors, few studies have analyzed the roles of MT in hematological malignancies. This review mainly describes the functions of MT in hematopoietic cells. Furthermore, through expression analyses of leukemias and lymphomas, the roles of MT in the biology of these diseases are particularly focused upon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.